

N-(3-trifluoromethylphenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(3-methylthiophenyl)-N-(4-*tert*-butylbenzyl)guanidine;
N-(5-acenaphthyl)-N-(3-iodobenzyl)guanidine;
N-(5-acenaphthyl)-N-(cinnamyl)guanidine;
N-(5-acenaphthyl)-N-(4-iodobenzyl)guanidine;
N-(5-acenaphthyl)-N-(4-trifluoromethoxybenzyl)guanidine;
and pharmaceutically acceptable salts thereof.

57. A method of any one of claims 51 through 56 wherein the mammal is suffering from hypertension.

58. A method of any one of claims 51 through 56 wherein the mammal is suffering or susceptible to a cardiac arrhythmia.

59. A method of any one of claims 51 through 56 wherein the mammal is suffering or susceptible to angina pectoris.

REMARKS

Claims 1-24 have been cancelled without prejudice, and claims 25-59 have been added. No new matter has been added. For instance, support for the new claims appears e.g. at pages 48-53 and the original claims of the application.

As an initial matter, Applicants respectfully request receipt of an initialed 1449 form indicating that the information submitted with the Information Disclosure Statement of August 20, 2000 has been considered and made of record. The undersigned also will contact the Examiner by telephone to further confirm that previously submitted Information Disclosure Statement.

Claims 16, 19 and 21-23 were rejected under 35 U.S.C. 103 over Weber et al. (U.S. Patent 5,190,976). The rejection is traversed.

The Weber patent recites N,N'-disubstituted guanidines, i.e. guanidine compounds that have multiple non-hydrogen substituents on each of two nitrogens of the guanidine moiety.

The pending claims call for compounds that have multiple non-hydrogen substituents on one nitrogen of a guanidine moiety.

Thus, compounds recited in Applicants' pending claims can include a guanidine moiety with *two* primary amino or unsubstituted imine (e.g. -NH₂ or =NH) groups, whereas in Weber the disclosed compounds have *one* primary amino or unsubstituted imine group of a guanidine moiety.

Such structural differences make clear that a *prima facie* case of obviousness has not been presented.

In view thereof, withdrawal of the rejection is requested.

It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

Respectfully submitted,



Christine C. O'Day (38,256)
Peter F. Corless (Reg. 33,860)
EDWARDS & ANGELL, LLP
Dike, Bronstein, Roberts & Cushman IP Group
P.O. Box 9169
Boston, Massachusetts 02209
(617) 439-4444